Ken Griffin Citadel Advisors
Ken Griffin founded Citadel, one of the world’s largest and most successful hedge funds. Starting his trading career from his Harvard dorm room at a young age, Griffin quickly developed a keen sense for markets and built Citadel into a global powerhouse with billions in assets under management. Known for his quantitative and technology-driven strategies, Griffin has also made headlines for significant philanthropic contributions, supporting causes in education, the arts, and public institutions. Over the years, he has earned recognition as one of the preeminent figures in modern finance.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Boeing
BA
|
+$830M |
| 2 |
UnitedHealth
UNH
|
+$769M |
| 3 |
Arthur J. Gallagher & Co
AJG
|
+$691M |
| 4 |
Amazon
AMZN
|
+$654M |
| 5 |
Bank of America
BAC
|
+$634M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
State Street SPDR S&P 500 ETF Trust
SPY
|
+$1.23B |
| 2 |
NVIDIA
NVDA
|
+$550M |
| 3 |
Spotify
SPOT
|
+$473M |
| 4 |
Citigroup
C
|
+$460M |
| 5 |
Boston Scientific
BSX
|
+$428M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 3.13% |
| 2 | Technology | 2.97% |
| 3 | Financials | 2.19% |
| 4 | Consumer Discretionary | 2.09% |
| 5 | Industrials | 1.9% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
12601
PUT
Anixa Biosciences
ANIX
$108M
| $38.7K | ﹤0.01% |
16,700
+10,000
| +149% | +$31.1K |
|
12602
CALL
Oric Pharmaceuticals
ORIC
$1.44B
| $38.7K | ﹤0.01% |
4,800
-3,000
| -38% | -$27.5K |
|
12603
PUT
X4 Pharmaceuticals
XFOR
$418M
| $38.7K | ﹤0.01% |
1,760
+1,020
| +138% | +$16.3K |
|
12604
CALL
Arteris
AIP
$1.39B
| $38.7K | ﹤0.01% |
3,800
-19,100
| -83% | -$158K |
|
12605
CALL
WisdomTree Yield Enhanced US Aggregate Bond Fund
AGGY
$923M
| $38.6K | ﹤0.01% |
900
-1,500
| -63% | -$65.5K |
|
12606
CALL
Future Fuel
FF
$245M
| $38.6K | ﹤0.01% |
7,300
+4,300
| +143% | +$24K |
|
12607
PUT
Fulton Financial
FULT
$4.72B
| $38.6K | ﹤0.01% |
2,000
| – | – |
|
12608
Xilio Therapeutics
XLO
$60.3M
| $38.5K | ﹤0.01% |
+2,880
| New | +$39.6K |
|
12609
CALL
Oportun Financial
OPRT
$355M
| $38.4K | ﹤0.01% |
9,900
-23,400
| -70% | -$75.5K |
|
12610
PUT
ALX Oncology
ALXO
$271M
| $38.4K | ﹤0.01% |
23,000
+16,000
| +229% | +$24.6K |
|
12611
PUT
Solid Biosciences
SLDB
$986M
| $38.4K | ﹤0.01% |
9,600
+3,200
| +50% | +$17.6K |
|
|
PHLT
12612
DELISTED
Performant Healthcare Inc
PHLT
| $38.4K | ﹤0.01% |
12,709
-38,453
| -75% | -$132K |
|
12613
CALL
Astronics
ATRO
$4.61B
| $38.3K | ﹤0.01% |
2,880
-1,560
| -35% | -$22.9K |
|
12614
CALL
Ducommun
DCO
$3.13B
| $38.2K | ﹤0.01% |
600
-1,100
| -65% | -$70.6K |
|
12615
PUT
Repay Holdings
RPAY
$329M
| $38.1K | ﹤0.01% |
5,000
-5,800
| -54% | -$46.3K |
|
12616
CALL
Southside Bancshares
SBSI
$986M
| $38.1K | ﹤0.01% |
1,200
-200
| -14% | -$6.79K |
|
12617
CALL
KraneShares Global Carbon Strategy ETF
KRBN
$132M
| $38.1K | ﹤0.01% |
1,300
+800
| +160% | +$24.7K |
|
|
CRSH
12618
CALL
YieldMax Short TSLA Option Income Strategy ETF
CRSH
$15.4M
| $38K | ﹤0.01% |
+620
| New | +$58.5K |
|
12619
Urban One Class A
UONE
$23.3M
| $37.9K | ﹤0.01% |
+2,461
| New | +$37.3K |
|
12620
CALL
Greenlight Captial
GLRE
$514M
| $37.8K | ﹤0.01% |
2,700
-9,400
| -78% | -$133K |
|
12621
PUT
Gerdau
GGB
$9.3B
| $37.7K | ﹤0.01% |
13,100
-11,700
| -47% | -$38.6K |
|
12622
CALL
Beam Global
BEEM
$25.1M
| $37.7K | ﹤0.01% |
11,900
+4,300
| +57% | +$17.7K |
|
12623
CALL
GoodRx Holdings
GDRX
$1.27B
| $37.7K | ﹤0.01% |
8,100
-120,300
| -94% | -$661K |
|
12624
CALL
Compugen
CGEN
$228M
| $37.6K | ﹤0.01% |
24,600
+15,200
| +162% | +$24.7K |
|
12625
ProShares UltraShort FTSE China 50 of ProShares Trust
FXP
$6.24M
| $37.6K | ﹤0.01% |
+1,037
| New | +$37.5K |
|
Similar funds
Ken Griffin's Q4 2024 Portfolio in Review
As of Q4 2024, Ken Griffin held 15,826 positions worth $578B, up 11% from $518B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
Ken Griffin deployed $35.2B of net new capital in Q4 2024, opening 1,745 new positions and adding to 6,428 existing holdings. Its largest new stake was Zoetis: 1,090,499 shares worth $178M.
By sector, the portfolio is most concentrated in Healthcare at 3.1% of assets, up from 2.9% a quarter earlier, followed by Technology and Financials.
On the sell side, the largest reduction was State Street SPDR S&P 500 ETF Trust, an estimated $1.23B trimmed.
- Ken Griffin's largest Q4 2024 buy was Zoetis: 1,090,499 shares worth $178M.
- Ken Griffin added most to Boeing in Q4 2024, an estimated $830M increase.
- Ken Griffin's biggest Q4 2024 reduction was State Street SPDR S&P 500 ETF Trust, cutting an estimated $1.23B.
- Ken Griffin fully exited Spotify in Q4 2024, selling an estimated $473M.
- Ken Griffin's ten largest holdings make up 31% of its $578B portfolio in Q4 2024.
- Ken Griffin opened 1,745 new positions and closed 1,423 in Q4 2024.
- Ken Griffin's portfolio value rose 11% quarter-over-quarter to $578B.
Based on Citadel Advisors's 13F filing for Q4 2024, filed 14 Feb 2025.